U.S. pharma large copyright scrapped two experimental weight loss tablets previous 12 months—a at the time-day-to-day tablet, lotiglipron, because of elevated liver enzymes and also a 2 times-everyday pill, danuglipron, because of powerful Unwanted side effects—but CEO Albert Bourla